Gregory Dupeyre

CEO of Auressens

The technology developed by Auressens allows the production of coatings having the reflective aspect of metal, while being only made of organic material.
The dyes constituting these coatings belong to families of innovative molecules which allow to reach many optical effects according to their nature.
The particularity of these dyes is their capacity to self-organize after their deposition on surface to form a pigmentary material having the appearance of metal, in particular that of gold.

Creation
2021
Fundraising
NC
Turnover
NC
Job creation
4

Traditionally, metallic pigments and deposits require the addition of dyes or colored topcoats to achieve a wide range of shades.
Auressens technology, on the other hand, is based on organic pigments which are at the origin of both the color and the metallic shine.

Marc Van Der Cruyssen

CEO of Abilycare

"In France, 1.4 million people are recognized as dependent and 12,000 people die from the consequences of a fall. These figures could be reduced if the signs of frailty were detected earlier in order to implement prevention programs. Our mission is therefore to respond to this prevention issue by measuring two biomarkers of general health: walking and balance. In this way, AbilyCare contributes to Goal 3 of sustainable development defined by the United Nations (UN): "Good health and well-being. "


Creation
09/07/2021
Fundraising
90K€
Turnover
70K€
Job creation
NC

Designed for and by practitioners and caregivers, AbilyCare solution can detect the precursor and reversible signs of frailty at any time in life.

Anthony Coutant

Co-founder of Hephia

"HephIA enables your organization to tame your big data into smart data.
Hephia's goal is twofold: on the one hand, to reduce the risks associated with data and AI projects, and on the other hand, to accelerate their release into production."

Creation
13/04/2021
Fundraising
90K€
Turnover
NC
Job creation
NC

HephIA offers a research-based unsupervised AI solution for taming massive data.


Fabrice Paublant

CEO of Orixha

"Today, the chances of survival from out-of-hospital cardiac arrest are around 10%. The ultra-rapid hypothermia solution developed by Orixha aims to significantly improve this prognosis and limit neurological sequelae for survivors."



Creation
01/01/2018
Fundraising
2,2M€
Turnover
NC
Job creation
2

Orixha develops the LV4C (Liquid Ventilation for Cooling) medical device. LV4C is based on a proprietary technological innovation that transforms the patient's lungs into a highly efficient heat exchange chamber with the blood.

Jérôme BECQUART

CEO of Brainvectis

"The pharmaceutical industry unsuccessfully spent tens of billions of euros to cure neurodegenerative diseases. It is time to accelerate the development of new approaches and new therapeutic methods. Brainvectis is developing a new approach of gene therapy that can be applied to both monogenic and non-genetic diseases."

Creation
14/08/2015
Fundraising
2 M€
Turnover
NC
Job creation
6

Brainvectis develops gene therapy products to treat neurodegenerative diseases. Our approach is to restore the metabolism of cholesterol disrupted in the brains of patients suffering from these diseases.
The start-up brainvectis was acquired by Asklepios BioPharmaceutical, Inc in 2020 for an undisclosed amount.

Nos start-up Nos start-up

The Pioneers, the Bold,
we bet on you.

Argument Theory

Argument Theory offers an Artificial Intelligence service for aiding and/or automating complex company decision-making problems in compliance with legal regulations.

Visit the site
Neurallys

Neurallys is developing a connected medical device to improve the quality of life of patients suffering from hydrocephalus.

Visit the site
Orixha

ORIXHA develops an innovative device for cooling patients within few minutes to improve their prognosis after a cardiac arrest.

Visit the site
SkinDermic

SkinDermic develops innovative small molecule drugs to treat infectious and inflammatory skin diseases.

Visit the site
Soléo-Ecosolutions

Soléo-écosolutions develops biocontrol solutions for fungal insects, based on natural molecules.

Visit the site
Telomium

Telomium is a biotechnology company developing a therapeutic vaccine for cancer immunotherapy.

Contact us
EverZom

EVerZom is at the service of regenerative medicine with a new biological tool: extracellular vesicles (EVs), today considered an alternative to cellular therapies.

Visit the site
Ermium Therapeutics

Ermium Therapeutics, is a biotechnology company developing innovative health products for autoimmune and inflammatory diseases.

Visit the site
Evora Biosciences

Evora biosciences is developing exosome-based treatments, the next generation of subcellular therapies.

Visit the site
Auressens

The technology developed by Auressens offers an alternative to metal, precious or not, in decorative & technical applications where the appearance of the metal or its optical properties are paramount.

Visit the site
SideROS

New molecules to fight cancer.

AbilyCare

AbilyCare can detect the early and reversible signs of frailty at any time of life.

Visit the site
Methys Dx

METHYS DX is a company specialized in the development and marketing of non-invasive biomarkers of pathologies including cancers as well as associated technologies.

Contact us
Persea

Persea is revolutionizing the treatment of solid cancers by developing the first treatment offering complete remission for liver cancer: BioTrojan.

Contact us
Cobot One

Cobot One develops innovative cobots with high mechanical robustness, speed, precision, capable of collaborating with a human operator safely and very easy to program.

PegmaTiss Biotech

PegmaTiss BioTech, specialize in tissue engineering, develops a new generation implant for dental tissue engineering and Orthopedic tissue repair.pédique.

Visit the site

Everything is accelerating.
What about you?

Erganeo is at your disposal.

your topic
For any information concerning personal data, consult the legal notices.